[HTML][HTML] Sepsis biomarkers and diagnostic tools with a focus on machine learning

M Komorowski, A Green, KC Tatham, C Seymour… - …, 2022 - thelancet.com
Over the last years, there have been advances in the use of data-driven techniques to
improve the definition, early recognition, subtypes characterisation, prognostication and …

[HTML][HTML] Evolving outcomes of extracorporeal membrane oxygenation during the first 2 years of the COVID-19 pandemic: a systematic review and meta-analysis

RR Ling, K Ramanathan, JJL Sim, SN Wong, Y Chen… - Critical Care, 2022 - Springer
Background Extracorporeal membrane oxygenation (ECMO) has been used extensively for
coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS) …

[HTML][HTML] Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single-cell transcriptomics

E Wyler, JM Adler, K Eschke, GT Alves, S Peidli, F Pott… - Molecular Therapy, 2022 - cell.com
For coronavirus disease 2019 (COVID-19), effective and well-understood treatment options
are still scarce. Since vaccine efficacy is challenged by novel variants, short-lasting …

Mass cytometry reveals a conserved immune trajectory of recovery in hospitalized COVID-19 patients

CE Burnett, TLH Okholm, I Tenvooren, DM Marquez… - Immunity, 2022 - cell.com
While studies have elucidated many pathophysiological elements of COVID-19, little is
known about immunological changes during COVID-19 resolution. We analyzed immune …

[HTML][HTML] Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients

J de Brabander, E Duijvelaar… - European …, 2022 - Eur Respiratory Soc
Background Imatinib reduced 90-day mortality in hospitalised coronavirus disease 2019
(COVID-19) patients in a recent clinical trial, but the biological effects that cause improved …

[HTML][HTML] Clinical sepsis phenotypes in critically ill COVID-19 patients

N Bruse, EJ Kooistra, A Jansen, RBE Van Amstel… - Critical Care, 2022 - Springer
Background A greater understanding of disease heterogeneity may facilitate precision
medicine for coronavirus disease 2019 (COVID-19). Previous work identified four distinct …

Machine learning approaches for phenotyping in cardiogenic shock and critical illness: part 2 of 2

JC Jentzer, C Rayfield, S Soussi, DD Berg… - JACC: Advances, 2022 - jacc.org
Progress in improving cardiogenic shock (CS) outcomes may have been limited by failure to
embrace the heterogeneity of pathophysiologic processes driving the underlying syndrome …

Immune modulation in sepsis, ARDS, and Covid-19—The road traveled and the road ahead

A Leligdowicz, MO Harhay, CS Calfee - NEJM evidence, 2022 - evidence.nejm.org
Immune Modulation in Sepsis, ARDS, and Covid-19 — The Road Traveled and the Road
Ahead | NEJM Evidence Skip to main content NEJM Evidence homepage Advanced Search …

[HTML][HTML] Benefits of using dapsone in patients hospitalized with COVID-19

BA Kanwar, A Khattak, J Balentine, JH Lee, RE Kast - Vaccines, 2022 - mdpi.com
Since the start of the SARS-CoV-2 pandemic, refractory and relentless hypoxia as a
consequence of exuberant lung inflammation and parenchymal damage remains the main …

[HTML][HTML] Renaissance of glucocorticoids in critical care in the era of COVID-19: ten urging questions

MS Winkler, MF Osuchowski, D Payen, A Torres… - Critical Care, 2022 - Springer
The 40-year-old experience with glucocorticosteroids (GCs) in the context of severe
infections is complex and troublesome. Recently, however, a clear indication for GCs in …